Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05681650

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Phase I/II Clinical Trial of HER2 Targeted HypoSti.CAR-T Cells in Treating Patients With HER2 Positive Local Advanced or Metastatic Solid Tumors

Sponsor: Chinese PLA General Hospital

Conditions HER2 Positive Advanced Solid Tumors

Interventions Albumin-bound paclitaxel Cyclophosphamide Fludarabine HypoSti.CAR-HER2 T cells

Updated 6 times since 2023 Last updated: Dec 11, 2023 Started: Oct 11, 2023 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on HER2 Positive Advanced Solid Tumors, this trial is actively recruiting participants. The trial is conducted by Chinese PLA General Hospital and has accumulated 6 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2023 — Jan 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Jun 2023 — Jul 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Feb 2023 — Jun 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese PLA General Hospital
Fudan University

Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China